Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

ADENOSCAN

ADENOSINE

Standard Dose
60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ADENOSCAN is listed in Drugs@FDA under application 020059 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ADENOSINE Form and strength SOLUTION;INTRAVENOUS - 60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASTELLAS Submission history Latest submission status date: 2014-08-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview ADENOSCAN is listed in Drugs@FDA under application 020059 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ADENOSINE Form and strength SOLUTION;INTRAVENOUS - 60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASTELLAS Submission history Latest submission status date: 2014-08-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.